MicroCHIPS granted new patent for implantable device

Drug delivery device developer MicroCHIPS, based in Waltham, MA, has been granted a U.S. Patent that, the company says, "provides broad coverage for the design and fabrication of reservoir-based medical devices used for implantable drug delivery systems." The patent, "Method of Controlled Drug Delivery from Implant Device" goes hand-in-hand with previously granted patents to help solidify the company's intellectual property in this space, the company said in a release.

"The granting of this patent provides the fundamental building blocks for programmable medical drug delivery implants to address various diseases such as diabetes, osteoporosis, heart disease and cancer," MIT researcher Robert Langer said in a release.

MicroCHIPS' technology originated at MIT based on research by Langer, Michael Cima and cofounder John Santini. The technology is currently part of a clinical trial to treat osteoporosis in women. The trial is evaluating precise delivery of human parathyroid hormone from a programmable, wireless implanted device, the release said.

- read the MicroCHIPS release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.